AR062165A1 - Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas - Google Patents
Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticasInfo
- Publication number
- AR062165A1 AR062165A1 ARP070103382A ARP070103382A AR062165A1 AR 062165 A1 AR062165 A1 AR 062165A1 AR P070103382 A ARP070103382 A AR P070103382A AR P070103382 A ARP070103382 A AR P070103382A AR 062165 A1 AR062165 A1 AR 062165A1
- Authority
- AR
- Argentina
- Prior art keywords
- isobutyl
- group
- extract
- preparation procedure
- forms
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- -1 alpha-isobutyl Chemical group 0.000 abstract 3
- IBLPTYJTKWQCDX-MOTAWSDJSA-N 5-[(1r)-1-[(1ar,4r,4ar,7s,7as,7br)-4-hydroxy-1,1,4,7-tetramethyl-1a,2,3,4a,5,6,7a,7b-octahydrocyclopropa[h]azulen-7-yl]-3-methylbutyl]-2,4,6-trihydroxybenzene-1,3-dicarbaldehyde Chemical compound C1([C@H](CC(C)C)[C@]2(C)[C@@H]3[C@H]([C@](CC[C@@H]4[C@H]3C4(C)C)(C)O)CC2)=C(O)C(C=O)=C(O)C(C=O)=C1O IBLPTYJTKWQCDX-MOTAWSDJSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940007062 eucalyptus extract Drugs 0.000 abstract 2
- 244000166124 Eucalyptus globulus Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- IBLPTYJTKWQCDX-UHFFFAOYSA-N euvimal-1 Natural products C1CC(C(CCC2C3C2(C)C)(C)O)C3C1(C)C(CC(C)C)C1=C(O)C(C=O)=C(O)C(C=O)=C1O IBLPTYJTKWQCDX-UHFFFAOYSA-N 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009103 reabsorption Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Utilizacion de un extracto deeucalipto para la preparacion de un medicamento destinado al tratamiento y/o a la prevencion de las afecciones o patologías que se derivan de un trastorno en la reabsorcion de neurotransmisores. La presente invencion se refiereigualmente a un nuevo extracto de eucalipto enriquecido caracterizado porque contiene al menos un compuesto de la formula (1) o una cualquiera de sus formas diastereoisoméricas: en la que R1 forma con el átomo de carbono al que está unido un grupo C=CH2, un grupo de formulas (2) y R2 representa un grupo isobutilo, alfa-isobutilo o beta-isobutilo; así como a su procedimiento de preparacion. Reivindicacion 4: Utilizacion segun la reivindicacion 3, caracterizada porque el compuesto de la formula (1) es el macrocarpal A (5-((1R)-1-((11S,7R)-7-hidroxi-3,3,7,11-tetrametiltriciclo(6.3.0.0(2,4))undec-11-il)-3-metilbutil)-2,4,6-trihidroxibenceno-1,3-dicarbaldehído) en el que R1 forma con el átomo de carbono al que está unido el grupo (3) y R2 representa un beta-isobutilo; y porque su fraccion másica en el extracto de eucalipto es superior o igual a 0,1% y estrictamente inferior a 3%.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0607201A FR2904557B1 (fr) | 2006-08-01 | 2006-08-01 | Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062165A1 true AR062165A1 (es) | 2008-10-22 |
Family
ID=37708427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103382A AR062165A1 (es) | 2006-08-01 | 2007-08-01 | Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20090324754A1 (es) |
| EP (1) | EP2049133A2 (es) |
| JP (1) | JP2010500974A (es) |
| KR (1) | KR20090034401A (es) |
| CN (1) | CN101511378A (es) |
| AR (1) | AR062165A1 (es) |
| AU (1) | AU2007283529A1 (es) |
| BR (1) | BRPI0714863A2 (es) |
| CA (1) | CA2659162A1 (es) |
| FR (1) | FR2904557B1 (es) |
| IL (1) | IL196788A0 (es) |
| MA (1) | MA30592B1 (es) |
| MX (1) | MX2009000673A (es) |
| NO (1) | NO20090951L (es) |
| NZ (1) | NZ574429A (es) |
| RU (1) | RU2445112C2 (es) |
| TN (1) | TN2009000018A1 (es) |
| TW (1) | TW200820961A (es) |
| UA (1) | UA99598C2 (es) |
| WO (1) | WO2008017752A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2926547B1 (fr) * | 2008-01-18 | 2010-04-23 | Pf Medicament | 5-°1-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h- cyclopropa°a!naphtalen-4-yl)-3-methylbutyl!-2,4,6-trihydroxy -1,3-benzenedicarboxaldehyde en tant que medicaments. |
| JP5602346B2 (ja) | 2008-06-17 | 2014-10-08 | 株式会社ロッテ | ユーカリ抽出物の調製方法 |
| GB2465228A (en) * | 2008-11-15 | 2010-05-19 | Athena Health Patents Inc | Analogues of phloroglucinols from eucalyptus plant varieties and related compounds and their use in treating neurodegenerative disorders |
| CN102085169B (zh) * | 2011-01-30 | 2012-08-29 | 广州中涵生物科技有限公司 | 一种使黑头溶解同步收细毛孔的制剂 |
| PT106278B (pt) * | 2012-04-26 | 2018-01-03 | Raiz Inst De Investigação Da Floresta E Papel | Método para a obtenção de um extrato rico em ácidos triterpénicos a partir da casca de eucalipto |
| KR102115037B1 (ko) * | 2013-12-04 | 2020-05-25 | 코웨이 주식회사 | 상고머리 야테 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물 |
| CN106231923A (zh) * | 2013-12-18 | 2016-12-14 | 斯拉毕思科股份公司 | 类囊体降低对可口食物欲望的用途 |
| CN109475586A (zh) | 2016-06-29 | 2019-03-15 | 康纳塞斯创新公司 | 脱羧的大麻树脂、其用途和制备其的方法 |
| CN109172554A (zh) * | 2018-09-06 | 2019-01-11 | 淮安安莱生物科技有限公司 | 大果桉醛c在制备治疗人肝癌的药物方面的应用 |
| KR102212193B1 (ko) | 2019-07-15 | 2021-02-03 | 박경호 | 인동등 및 유칼립투스 추출물을 유효성분으로 포함하는 인지기능장애 예방 또는 치료용 조성물 |
| JP7506371B2 (ja) * | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2329297A1 (fr) * | 1975-10-29 | 1977-05-27 | Rougier Yves | Inhalateur buccal |
| JP3365782B2 (ja) * | 1990-11-22 | 2003-01-14 | 株式会社ロッテ | 新規マクロカルパール類及びその製造法 |
| DE4447336C2 (de) * | 1994-12-31 | 1996-12-19 | Goebel Hartmut J Dr Med Habil | Verwendung eines Gemisches aus Cineol und Menthol |
| JPH08198765A (ja) * | 1995-01-31 | 1996-08-06 | Hayami Kinugawa | 鎮痛用医薬組成物 |
| JPH11137232A (ja) * | 1997-08-02 | 1999-05-25 | Ever Bright Ind Corp | ハーブ製品 |
| US20010036488A1 (en) * | 2000-01-18 | 2001-11-01 | Syuichi Hayashi | Anti-obestic composition |
| JP4809980B2 (ja) * | 2000-01-18 | 2011-11-09 | 長岡香料株式会社 | 抗動脈硬化症剤 |
| MXPA04006039A (es) * | 2001-12-19 | 2004-09-27 | The Quigley Corp | Metodo para el tratamiento de afecciones vasculares y neuronales perifericas. |
| JP4979181B2 (ja) * | 2003-01-31 | 2012-07-18 | 株式会社ヤクルト本社 | グリケーション阻害剤及びその利用 |
| JP2005272431A (ja) * | 2004-03-24 | 2005-10-06 | Yukio Kitagawa | アロマセラピー品 |
-
2006
- 2006-08-01 FR FR0607201A patent/FR2904557B1/fr not_active Expired - Fee Related
-
2007
- 2007-07-27 UA UAA200901761A patent/UA99598C2/ru unknown
- 2007-07-27 US US12/309,754 patent/US20090324754A1/en not_active Abandoned
- 2007-07-27 KR KR1020097004185A patent/KR20090034401A/ko not_active Ceased
- 2007-07-27 CN CNA2007800334763A patent/CN101511378A/zh active Pending
- 2007-07-27 EP EP07823364A patent/EP2049133A2/fr not_active Withdrawn
- 2007-07-27 MX MX2009000673A patent/MX2009000673A/es not_active Application Discontinuation
- 2007-07-27 AU AU2007283529A patent/AU2007283529A1/en not_active Abandoned
- 2007-07-27 CA CA002659162A patent/CA2659162A1/fr not_active Abandoned
- 2007-07-27 WO PCT/FR2007/001309 patent/WO2008017752A2/fr not_active Ceased
- 2007-07-27 RU RU2009107166/15A patent/RU2445112C2/ru not_active IP Right Cessation
- 2007-07-27 JP JP2009522297A patent/JP2010500974A/ja active Pending
- 2007-07-27 BR BRPI0714863-1A patent/BRPI0714863A2/pt not_active IP Right Cessation
- 2007-07-27 NZ NZ574429A patent/NZ574429A/en not_active IP Right Cessation
- 2007-07-31 TW TW096127881A patent/TW200820961A/zh unknown
- 2007-08-01 AR ARP070103382A patent/AR062165A1/es not_active Application Discontinuation
-
2009
- 2009-01-19 TN TN2009000018A patent/TN2009000018A1/fr unknown
- 2009-01-20 MA MA31575A patent/MA30592B1/fr unknown
- 2009-01-29 IL IL196788A patent/IL196788A0/en unknown
- 2009-03-02 NO NO20090951A patent/NO20090951L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA30592B1 (fr) | 2009-07-01 |
| CN101511378A (zh) | 2009-08-19 |
| NZ574429A (en) | 2012-01-12 |
| UA99598C2 (ru) | 2012-09-10 |
| MX2009000673A (es) | 2009-02-04 |
| BRPI0714863A2 (pt) | 2013-05-21 |
| TW200820961A (en) | 2008-05-16 |
| RU2445112C2 (ru) | 2012-03-20 |
| CA2659162A1 (fr) | 2008-02-14 |
| EP2049133A2 (fr) | 2009-04-22 |
| AU2007283529A1 (en) | 2008-02-14 |
| FR2904557B1 (fr) | 2010-04-30 |
| US20090324754A1 (en) | 2009-12-31 |
| WO2008017752A3 (fr) | 2008-04-10 |
| FR2904557A1 (fr) | 2008-02-08 |
| IL196788A0 (en) | 2009-11-18 |
| KR20090034401A (ko) | 2009-04-07 |
| RU2009107166A (ru) | 2010-09-10 |
| WO2008017752A2 (fr) | 2008-02-14 |
| TN2009000018A1 (fr) | 2010-08-19 |
| NO20090951L (no) | 2009-04-24 |
| JP2010500974A (ja) | 2010-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062165A1 (es) | Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas | |
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| EA201070988A1 (ru) | Противовирусные терапевтические средства | |
| UY28473A1 (es) | Nuevos compuestos | |
| EA201491335A1 (ru) | Бигуанидные композиции и способы лечения метаболических расстройств | |
| CO6382129A2 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o provencion de diabetes | |
| EA201370208A1 (ru) | Формы рифаксимина и их применение | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
| EA200900023A1 (ru) | Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли | |
| EA201100921A1 (ru) | Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ | |
| CO6270312A2 (es) | Moduladores de gpr40 bifenilo-sustituidos | |
| UY30812A1 (es) | Sulfonatos { 2-amino-4-[r-fenil]-1-metil-5-oxo-4,5-dihidro-1 h-imidazol-4-il}fenil sustituidos, composiciones conteniéndolos y aplicaciones | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
| UY31065A1 (es) | Heterociclos ciclicos | |
| CO6220948A2 (es) | Derivados de ciclohexano espirociclico | |
| MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
| DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
| UY29079A1 (es) | Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| CO6382089A2 (es) | Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias | |
| DOP2005000025A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| EA201001586A1 (ru) | Соединения и композиции в качестве ингибиторов itpkb | |
| EA200900065A1 (ru) | Ингибиторы глицинового переносчика-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |